Option Chain

Castle Biosciences Inc

CSTLNASDAQ · USD

32.52USD-1.68 (-4.92%)

6610

Castle Biosciences Inc (CSTL) Option Chain

Castle Biosciences Inc trades at $32.52, down 4.92%, with an IV Rank of 83.33%. This is high versus the past year, and the company carries a market cap of $1,045M in the Diagnostics & Research industry. On the Nov 20, 2026 chain, the at the money $35.00 strike shows calls at $1.60 / $4.30 and puts at $1.00 / $4.90, both carrying about $1.71 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $40.00 calls, at 752 contracts, and the $30.00 puts, at 750, as of Nov 5, 2026.

Tracking the CSTL option chain helps you see every strike and expiry on Castle Biosciences Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CSTL options activity at a glance. Use our scanner to monitor the CSTL option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CSTL stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where CSTL options are being actively traded, and where they are not.

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
1.00	0	0	1.73	10.02	9.50	14.00	22.50	-34.21	—	4.90	0.00	4.90	0	0	99.00
4.25	0	0	1.88	7.52	7.30	11.50	25.00	-26.90	—	3.50	0.00	3.50	0	0	95.75
24.98	2	0	2.78	2.52	3.10	7.50	30.00	-12.28	—	3.50	0.00	3.50	750	5	75.02
58.34	6	0	2.95	0.00	1.60	4.30	35.00	+2.34	1.00	4.90	2.48	0.47	0	1	41.66
83.59	45	752	1.08	0.00	0.40	1.75	40.00	+16.96	4.20	8.50	7.48	-1.13	0	0	16.41

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryDiagnostics & Research
SectorHealthcare
IV Rank83.33% High
Market cap (M$)1,045
52 weeks high-22.76%
52 weeks low93.00%
Analyst recommendationStrong Buy
1.10
Target price$46.70
43.60% above the current stock price
Dividend—
Payout ratio—
Earnings date2026-11-05
P/E—
Future P/E—
EPS (ttm)-0.65
EPS growth next 5 years25.22%

As of Nov 5, 2026

Browse all Option Chain tickers